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PERSPECTIVES
disorders and schizophrenia — has become
one of the most profitable sectors of the phar-
maceutical market. CNS drugs account for 11
of the top 25 drugs on the US market, with
annual US sales in excess of US $17 billion
(2002 sales figures). Additionally, it is now
widely accepted that moderately effective
treatments exist for most of the common
CNS diseases, including schizophrenia,
depression, anxiety disorders, insomnia,
migraine headaches, chronic pain and seizure
disorders. This article will focus on the two
largest sectors of the CNS drug market:
atypical antipsychotic drugs for schizophrenia
and related disorders, and antidepressants for
depression and anxiety disorders.
Despite the acknowledged potential of
CNS therapeutic agents, few drugs with truly
novel mechanisms of action have been intro-
duced in the past several decades. Indeed, the
most widely prescribed drugs — the serotonin-
selective reuptake inhibitors (SSRIs) and
atypical antipsychotic drugs — represent
only marginal advances over the prototypes
zimelidine (discovered in 1971 (REF. 2)) and
clozapine (discovered in 1958 (REF. 3)).
Because the aetiology of depression and
schizophrenia is unknown, choosing the
appropriate molecular target for drug dis-
covery is especially risky. In terms of aetiology,
it is now widely accepted that the major
mental illnesses are polygenic4,5, with substan-
tial environmental and, perhaps, epigenetic
components. The polygenic and non-genetic
components of major CNS diseases makes
the use of genetically engineered mice to
provide validated models for drug discovery
efforts precarious6.
Another fundamental difficulty with
developing novel CNS therapeutics is the
appreciation that the most widely prescribed
CNS medications, especially those for mood
disorders (for example, lithium, anticonvul-
sants and antidepressants7) and schizophrenia8
have complex and ill-defined mechanisms of
action. As will be summarized below, the dis-
covery that the most clinically effective CNS
drugs are pharmacologically complex, with
pleiotypic actions (that is, they act as ‘magic
shotguns’), has made the development of
‘magic bullets’ (that is, drugs selective for a
single molecular target) less likely.
Why ‘dirty’ drugs might be better 
Even though clozapine was discovered nearly
50 years ago3, it remains the ‘gold standard’
atypical antipsychotic drug because of the
absence of debilitating extra-pyramidal side-
effects and demonstrated clinical superiority
in treating schizophrenia9 and in reducing
suicidality10. However, clozapine is also
associated with severe and potentially life-
threatening side effects, including an increased
risk of agranulocytosis, seizures, weight gain
and diabetes, and is therefore typically pre-
scribed only for individuals with ‘treatment-
resistant’ schizophrenia. Clozapine has a highly
complex pharmacological profile, with high



























-subtypes) and other biogenic amine
receptors (REF. 8 and references cited therein).
FIGURE 1 shows the distribution of some of
the receptors targeted by clozapine in relation
to various molecular targets implicated by
genetic studies of schizophrenia (see REFS 4,5
for details). As can be seen in FIG. 1, many of
the genes implicated in the aetiology of schizo-
phrenia are found in anatomical loci where
they could, directly or indirectly, modulate
glutamatergic and dopaminergic neurotrans-
mission in the frontal cortex. Clozapine is
Most common central nervous system
disorders — such as depression, bipolar
disorder and schizophrenia — seem to be
polygenic in origin, and the most effective
medications have exceedingly complex
pharmacologies. Attempts to develop
more effective treatments for diseases
such as schizophrenia and depression by
discovering drugs selective for single
molecular targets (that is, ‘magic bullets’)
have, not surprisingly, been largely
unsuccessful. Here we propose that
designing selectively non-selective drugs
(that is, ‘magic shotguns’) that interact with
several molecular targets will lead to new
and more effective medications for a variety
of central nervous system disorders.
Despite their enormous potential to alleviate
human suffering, before the introduction of
fluoxetine (Prozac; Eli Lilly) in the late 1980s
central nervous system (CNS) therapeutics
were not widely embraced as either highly
reliable or profitable. This is despite the fact
that from the 1960s to the 1970s selected areas
of CNS drug discovery yielded profitable
drugs (for example, Valium, Milltown and
Haldol). This was due, in part, to the lack of
suitable animal models, disagreements
regarding the biological basis of many dis-
orders, uncertainty regarding the ultimate
mechanism(s) of action and the clinical
ineffectiveness of many CNS medications1.
During the past two decades, CNS drug dis-
covery — particularly in the areas of mood
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Figure 1 | Neuronal circuits implicated in schizophrenia aetiology and treatment. Shown is a schematic diagram of the wiring of the frontal cortex,
emphasizing inputs into cortical glutamatergic pyramidal neurons. Some of the various molecular targets implicated as risk factors for schizophrenia are
shown, including calcineurin (CN) γ-subunit, the D1- and D3-dopamine receptors (D1, D3) and metabotrophic glutamate receptor 3 (mGluR3). Other molecular
targets not shown include catechol-O-methyltransferase, reelin, dysbindin, regulator of G-protein signalling-4 and neuregulin (see REFS 4,5 and references
cited therein). Receptors at which clozapine is an antagonist are depicted in red and those at which clozapine is a partial agonist are shown in green (see REF.
8 and references cited therein) and include the following: 5-HT1A- and 5-HT2A-serotonin, D1-, D2- and D3-dopamine, α1- and α2-adrenoceptors. For the
purposes of clarity, not all of the various molecular targets implicated as risk factors for schizophrenia or those occupied by clozapine are shown. For the sake
of simplicity, many other neuronal and biochemical interactions are omitted. GABA, γ-aminobutyric acid; GLU, glutamate; mGluR3, metabotrophic glutamate
receptor 3; NMDA, N-methyl-D-aspartate; VTA, ventral tegmental dopamine neuron.
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In addition to improving the core symp-
toms of schizophrenia, such as hallucinations
and delusions, atypical antipsychotic drugs as
a class modestly improve cognition18, though
it is unknown how these cognition-enhancing
actions are mediated. Current hypotheses
suggest that the cognition-enhancing actions





20 receptors, and to their
abilities to enhance prefrontal cortical
dopamine release21 (FIG. 1).
Many attempts, largely unsuccessful, have
been made to develop drugs that target the
‘magic receptor’ responsible for clozapine’s
salutary effects in schizophrenia and related
disorders and, thereby, yield novel atypical
antipsychotic drugs. For instance, D
4
-selective





antagonism23, are ineffective in
thought to normalize glutamatergic and
dopaminergic neurotransmission in schizo-
phrenia, thereby ameliorating symptoms, via
complex interactions with a large number of
molecular targets (FIGS 1,2). These pleiotypic
actions of clozapine are probably responsible
for its exceptionally beneficial actions in
schizophrenia and related disorders9,10.
A graphical representation of the relative
affinity values of clozapine and a number of
other atypical antipsychotic drugs (aripipra-
zole, ziprasidone, zotepine, quetiapine, olanza-
pine, risperidone) and typical antipsychotic
drugs (haloperidol, chlorpromazine) at a por-
tion of the receptorome (that is, that portion of
the proteome comprising receptors) is shown
in FIG. 2. As can be seen, most of the presently
approved atypical antipsychotic drugs have a
complex pharmacology, with appreciable
affinities for a variety of biogenic amine
receptors. Given the huge potential market for
atypical antipsychotic drugs (~US $10 billion
annually), great effort has been devoted to
uncovering the receptors responsible for effec-
tiveness, for atypicality and for side effects. The
idea has been that if one could design drugs
that targeted the appropriate receptors, one
could develop atypical antipsychotic drugs
that are more effective than clozapine and
have fewer side effects. These efforts will be
furthered in the future by the precise delin-
eation of the areas of the brain in which the
drug exerts its beneficial effects, as well as char-
acterization of the intracellular biochemical
pathways contributing to both effectiveness
and the development of side effects.
‘S2/D2’ drugs: not quite clozapine 
The first ‘non-clozapine’ atypical to be mar-
keted was risperidone, which potently blocks
the effects of lysergic acid diethylamide (LSD)




analysis of receptor pharmacology of a
number of typical and atypical antipsychotic
drugs led Meltzer12 and others13 to propose
that the single distinguishing feature of an
atypical antipsychotic drug was a relatively









hypothesis of atypicality’). Sub-
sequently, several atypical antipsychotic drugs





terion, including olanzapine, ziprasidone,
zotepine and quetiapine. Although these
drugs represent an advance in the treatment of
schizophrenia, none of the presently approved
atypical antipsychotic drugs is better than





atypicals’ are not without serious side
effects, including weight gain and the asso-
ciated metabolic sequelae of diabetes and
hypercholesterolaemia16. In this regard, recent








— sites for which many atypical antipsychotic
drugs have high affinity — for causing weight











example, ziprasidone) are less likely to induce
weight gain. Because other CNS medications
that induce weight gain, such as amitryptiline,
mirtazepine and imipramine (see PDSP K
i








affinities, these data strongly imply that







receptors will be less likely to
induce the metabolic side effects of many of
the presently marketed drugs.




























































































































Figure 2 | Screening the receptorome reveals multiple molecular targets implicated in
antipsychotic drug actions. The affinity (Ki) values for clozapine and a large number of other biologically
active compounds at various receptors can be found at the PDSP Ki Database (see Further Information);
the database is part of the National Institute of Mental Health Psychoactive Drug Screening Program (see
Further Information) and represents the largest database of its kind in the public domain. At present, the
PDSP Ki database has >26,000 Ki values for more than 300 receptors.
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postsynaptic antagonist and would therefore
‘stabilize’ dopaminergic neurotransmission.
This notion of ‘anatomical selectivity’ is diffi-
cult to reconcile with later findings that
aripiprazole is a D
2
partial agonist at post-
synaptic pituitary D
2
receptors in vitro and
in vivo33. Likewise, the D
2
partial agonism
has been inconsistently replicated, with some
groups reporting that aripiprazole is a high-
affinity partial agonist in vitro34, and others
reporting that aripiprazole is a D
2
antagonist
in vivo and in vitro35. By contrast, Lawler et al.36
proposed that aripiprazole was ‘functionally
selective’ and that the agonist properties of
aripiprazole were entirely dependent on the
cellular milieu in which it was studied. As a
result, it was proposed36 that aripiprazole
might function as a D
2
antagonist, agonist or




in a particular cell. This notion is similar to
the idea of agonist-directed trafficking of
receptors (see REF. 37 for a recent review), an
idea originally proposed many years ago38.
This idea proposes that receptors can couple
to several signal transducing molecules and
suggests that “selective agonists and antago-
nists might be developed which have spe-
cific effects on a particular receptor-linked
effector system.”38
When the various competing hypotheses
of aripiprazole’s actions were tested, we
found39, in support of the hypothesis of
Lawler et al.36, that the actions of aripiprazole
were entirely dependent on the cellular
milieu. Interestingly, we also discovered39
that aripiprazole had a robust pharmacologi-
















) receptors. So although
aripiprazole is clearly a functionally selective
partial agonist, its complex pharmacology
precludes us from concluding that its bene-
ficial actions in schizophrenia are due solely
to partial agonism of D
2
receptors. It is more
likely that the balance of partial agonism and
antagonism at a multiplicity of receptors is
responsible for its efficacy in schizophrenia
and related disorders. Taken together, these
findings have profound implications for
CNS drug discovery, because they imply that
simply developing selective low-efficacy D
2
partial agonists will not yield effective
antipsychotic drugs, but that D
2
partial ago-
nists that functionally interact with various
5-HT and dopamine receptors might be
effective. Therefore functionally non-selective
dopamine agonists might represent a new
generation of atypical antipsychotic drugs,
with aripiprazole being the first member of
this class.
schizophrenia, it was found to be effective for
a short period (~one week), after which clinical
efficacy was lost — presumably due to receptor
desensitization28. Because (–)PPP has sub-








PDSP Database, Further Information), it is
conceivable that the ineffectiveness of (–)




actually worsened psychotic symptoms, per-








On the basis of these early trials, it was
unclear whether (–)PPP’s lack of efficacy
beyond one week was due to either inadvertent
interaction with psychotomimetic receptors
(for example, σ
1
-adrenoceptor) or the rela-
tively high intrinsic activity of (–)PPP leading
to desensitization. Several other D
2
partial
agonists, including terguride, OPC-4392,
pramipexole and SDZ HDC 912, have now
been tested in schizophrenia, mainly unsuc-
cessfully30. To date, only aripiprazole (OPC
14597), a weak D
2
partial agonist31, has shown
efficacy for schizophrenia32, although con-
siderable controversy exists regarding its
mechanism of action (BOX 1).
Kikuchi et al.31 originally proposed that
aripiprazole was a presynaptic agonist and a
treating schizophrenia. Likewise, the 5-HT
2A
selective compound M100907 (REF. 24) failed
to reduce symptoms to the same extent as
haloperidol (a typical antipsychotic drug




fared better in comparison with haloperidol25
(TABLE 1). There have also been suggestions






actions might be effective antipsychotic drugs
but, so far, none have shown efficacy in clinical
trials (see REF. 8 and references cited therein).
TABLE 1 lists a number of other ‘magic bullets’
which, with few exceptions, were shown to
lack efficacy in schizophrenia.
Partial agonists for schizophrenia 
Some years ago, Carlsson proposed that (–)-
3-(3-hydroxyphenyl)-N-n-propylpiperidine
((–)PPP), by virtue of its autoreceptor agonist
properties, might represent a prototype for a
new family of atypical antipsychotic drugs27.
Carlsson’s notion was that a partial agonist
would normalize or ‘stabilize’ dopaminergic
neurotransmission in a way that would be
salutary for both the positive and negative
symptoms of schizophrenia. Two potential
compounds were subsequently tested: (–)PPP





agonism). When (–)PPP was tested in
Table 1 | Non-D2 dopamine antagonists in schizophrenia are inferior
Receptor Representative Results versus Results versus References
compound placebo comparator
5-HT2A M100907 Better Worse
5-HT2A/2C SR46349B Better Similar 25
5-HT6 SB271046 In Phase I NA *see footnote
5-HT2A/D4 Fananserin Potentially worse or NA 23
similar to placebo
D2-dopamine (–)PPP Worse with NA 28
partial agonist moderate efficacy
D3-dopamine (+)-UH232 Worse NA 29
partial agonist
D3-dopamine SB-277011 In trials NA 52
D4-dopamine L-745,870 Potentially worse or NA 53
similar to placebo
CB1 SR-141716 Worse Worse 25
cannabinoid
Sigma BMY-14802 Similar to placebo NA 54
Sigma Panamesine Better (small trial) NA 55
NK3 SR142801 Better Same 25
NT1 SR48692 Worse Worse 25
Glutamate D-cycloserine Similar to placebo with NA 56,57
marginal effect on negative 
symptoms; may augment 
actions of atypical 
antipsychotic drugs
* See http://science.gsk.com/pipeline/pipeline2002oct.pdf for details. 5-HT, serotonin; NK, neurokinin; 
NT, neurotensin.
© 2004 Nature Publishing Group
P E R S P E C T I V E S
that the large-scale, automated and random
screening of libraries of compounds enriched
for activity at CNS targets, using mainly
behavioural assays, will yield compounds with
novel and, possibly improved, efficacies for a
variety of CNS diseases. These approaches
carry with them the advantage of examining
responses to drugs at the level of entire organ-
isms, and therefore in the context of their
biological functioning, rather than in overly
simplified experimental systems, for example,
as in isolated in vitro binding studies.
Another approach is a genomic one in
which compounds are screened solely on
the basis of their abilities to modify the
Non-selective antidepressants?
If ‘dirty’ drugs are better for treating schizo-
phrenia than selective (‘clean’) ones, what
about other CNS disorders? TABLE 2 lists the
current classes of antidepressants, ranking
them by their relative effectiveness in treating
depression. The most effective treatment for
depression — electroconvulsive therapy (ECT)
— alters the dynamics of a vast number of
neurotransmitters and neuromodulators, and
has profound effects on intracellular signalling
pathways related to signal transduction and
mitogenesis7. Indeed, very recent studies imply
that the pleiotypic actions of antidepressants
on signal transduction and neuronal mitogen-
esis are required for the beneficial actions of
antidepressants on mood40. Likewise, so-called
‘dual-action’antidepressants, which inhibit the
reuptake of both 5-HT and other biogenic
amines (for example, dopamine and nor-
adrenaline), have been shown to be more effec-
tive than ‘single-action’antidepressants such as
the SSRIs41,42. As an added benefit, the ‘dual-
action’ antidepressants also seem to effectively
treat chronic pain43. Finally, recent genetic
studies have implied that depression, like
schizophrenia, is a complex disorder with
linkage to several genes44 , including many
that converge on the transcription factor
cAMP-responsive element binding protein-1
(CREB1). These results imply that improved
treatments for mood disorders are likely to arise
from drugs with several mechanisms of action,
and that studies that connect new knowledge
of genetic linkage of these diseases in humans
with those of changes in gene regulation in dis-
ease, as well as after treatment, are likely to be
helpful in the development of new therapies.
Implications for CNS drug discovery
Given that selectively non-selective drugs are
likely to be more beneficial than single-
action agents in many CNS disorders, how
best to develop them? Clearly, conventional
approaches relying on high-throughput
screening (HTS) of cloned human molecular
targets and the subsequent optimization of
these ‘single-target agents’ is not likely to
yield selectively non-selective agents, except,
perhaps, by chance. Structure-based drug
design approaches in which ligands are
designed to interact with the correct subset
of molecular targets are also not likely to be
successful. This is because many of the mol-
ecular targets selected have a high degree of
structural similarity and designing drugs to
target a subset of them is not likely to be
successful (see REF. 63 for discussion).
The implication of these findings is that
the screening of small molecules by non-
conventional approaches should be considered.
Conceptually, at least two non-conventional
approaches for discovering ‘magic shotguns’
can be envisioned: behaviour-based screening
and genomic approaches. The first, which
has been dubbed ‘HTS’-based behavioural
screening’45,46, relies on the semi-automated
screening of candidate drugs in broad-based
behavioural assays. At least two novel anti-
depressants — YKP10A and INN 00835 —
were discovered using this approach. Neither
drug seems to have appreciable affinity for any
known antidepressant drug target, including
various biogenic amine receptors and trans-
porters47, and both have demonstrated effec-
tiveness in early-phase trials48,47. It is probable
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Box 1 | Partial functionally selective agonists for schizophrenia?  
The figure shows three different proposed models of aripiprazole action. In these various
models, receptors coloured green are activated by aripiprazole and those coloured red are
antagonized; receptors colourd yellow can be partially activated by aripiprazole, depending on
the assay conditions. In panel a, the anatomical specificity model is highlighted. This model
originally proposed that partial agonists which are effective in treating schizophrenia have
differential actions at pre- and postsynaptic D
2
dopamine receptors31. This model proposed that
aripiprazole, for instance, is a presynaptic agonist and a postsynaptic antagonist; these dual
actions thereby ‘normalize’ dopaminergic signalling. In panel b, the density-dependent partial
agonist model34 is shown schematically. This model, which relies on classical receptor theory,
proposes that aripiprazole is a partial agonist whose actions depend solely on the relative density
of D
2
-dopamine receptors. As such, in brain regions in which relatively high concentrations of
D
2
-dopamine receptors exist, drugs like aripiprazole would be partial agonists, whereas in brain
regions with relatively low concentrations of D
2
receptors exist aripiprazole would function as an
antagonist. In panel c, we show our conceptualization of the functional selectivity model. This
model proposes that aripiprazole’s partial agonist actions at a variety of G-protein-coupled
receptors (GPCRs) are dependent on the precise cellular complement of receptors and G-proteins36
and relies on our current understanding of GPCR actions. This model predicts that partial
agonists, such as aripiprazole, will have a multiplicity of actions, functioning as agonists, partial
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drugs — ‘magic shotguns’ — could be dis-
covered by combining behavioural and
genomics-based screening. Once leads are
discovered, potential toxicities could be rela-
tively easily ‘designed out’by counter-screening
approaches combined with straight-forward
medicinal chemistry approaches. Such magic
shotguns, or selectively non-selective drugs,
are likely to represent highly effective and
novel treatments for major CNS disorders.
The rational discovery, optimization and
eventual marketing of selectively non-selective
drugs will end our reliance on serendipity as
the driving force for effective drug discovery
for CNS disorders. On the other hand, in a
gene K+ channel for arrhythmias50 and the
5-HT
2B
receptor for fenfluramine-like valvular
heart disease51). In addition, it might prove
possible to use combinations of compounds to
‘fine-tune’ these gene regulatory signatures.
The end of serendipity?
Historically, serendipity has been the driving
force in the discovery of novel and highly
effective drugs for CNS disorders. Not sur-
prisingly, the most clinically effective treat-
ments for depression and schizophrenia,
and perhaps other disorders, continue to be
the ones with the most nonspecific actions.
It is likely that selectively non-selective
coordinated expression of gene families. In this
approach, compounds with known beneficial
actions and pleiotypic actions (for example,
lithium, clozapine) are screened in vivo and
in vitro for their effects on coordinated gene
expression. Once gene ‘signatures’ are dis-
covered, compound libraries are subsequently
screened to discover small molecules which,
when administered in vitro and in vivo, yield
similar signatures; such an approach is now
being undertaken by Psychiatric Genomics,
Inc.49. Lead compounds can then be optimized
to eliminate interactions with potentially toxic
molecular targets (for example, H
1
receptor for
weight gain17, human ether-a-go-go-related
Table 2 | Antidepressants with complex modes of action are superior to single-action antidepressants
Prototypical Class Mode* Molecular Phase of testing Efficacy vs SSRI Company
drug target(s)
Electro- Somatic therapy C Undefined In use for decades Greater efficacy58 None
convulsive 
therapy
Imipramine Tricyclic C NET, SERT,  In use for decades Slight advantage41 Generic
antidepressant 5-HT2A, 5-HT2C,    
5-HT6, α1-adren-
ergic, muscarinic
Fluoxetine Serotonin-selective S SERT In use for >10 years N/A Eli Lilly
reuptake inhibitor
Venlafaxine Dual serotonin/ C NET; SERT In use 10 years Slight advantage41,42,59 Wyeth
norepinephrine 
reuptake inhibitor 
Pindolol 5-HT1A partial C 5-HT1A Several double-blind, Combination > than Generic
agonist/SSRI placebo controlled clinical SSRI alone in
combination trials completed; both uncomplicated 
drugs approved for use depression60 but not 
in refractory or chronic 
depression61
Duloxetine Dual serotonin/ C NET; SERT NDA submitted Unknown; predicted to Eli Lilly 
norepinephrine be >than SSRIs
reuptake inhibitor
Gepirone 5-HT1A partial S 5-HT1A NDA submitted; several  Unknown; Glaxo Smith 
agonist 5-HT1A partial agonists predicted to Kline
have been previously be < or = to SSRIs
tested as single agent 
treatments for depression 
with modest success
Memantine NMDA antagonist S NR2B NDA submitted for Unknown; predicted Forrest
Alzheimer’s; in use in Europe to be < or = to SSRIs 
for decades; preclinical 
research suggests efficacy
Aprepitant NK1 antagonist S NK-1 Phase III favourable Discontinued;  Merck
marginally effective
Agomelatine Melatonin/5-HT C MT-1; 5-HT2B; Phase III favourable Unknown; could be Servier
receptor antagonist 5-HT2C superior to SSRIs
Nemifitide Unknown C‡ Unknown Phase II/III favourable Unknown; dropped InnaPharma
(INN 00835) from further testing due 
to toxicity
SB 723620 CRF1 S CRF1 Phase I Unknown; predicted to Glaxo Smith 
be < or = to SSRIs Kline
SNAP-7941 MCH-1 S MCH-1 Preclinical Unknown; predicted to  Synaptic 
be < or = to SSRIs Pharmaceuticals
YKP-10A Unknown C‡ Unknown Phase II favourable Unknown SK Corporation 
*C, complex mode of action; S, simple mode of action. ‡Presumed.
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recent colloquium sponsored by the Collegium
Internationale Neuro-Psychopharmaco-
logicum, Arvid Carlsson has argued that the
field of CNS drug discovery is likely to con-
tinue to depend very much on serendipity.
The approaches he suggested to facilitate these
serendipitous discoveries are very similar to
those outlined above, although we would
argue that the results of such searches will not
be serendipitous at all, but rather the result of
looking for the right thing (magic shotguns)
in the right place and at the right time.
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